WO2005004906A3 - Verwendung von dp iv- und apn inhibitoren zur behandlung dermatologischer erkrankungen mit hyperproliferation und veränderten differenzierungszuständen von fibroblasten - Google Patents

Verwendung von dp iv- und apn inhibitoren zur behandlung dermatologischer erkrankungen mit hyperproliferation und veränderten differenzierungszuständen von fibroblasten Download PDF

Info

Publication number
WO2005004906A3
WO2005004906A3 PCT/EP2004/007377 EP2004007377W WO2005004906A3 WO 2005004906 A3 WO2005004906 A3 WO 2005004906A3 EP 2004007377 W EP2004007377 W EP 2004007377W WO 2005004906 A3 WO2005004906 A3 WO 2005004906A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibroblasts
inhibitors
hyperproliferation
treatment
diseases involving
Prior art date
Application number
PCT/EP2004/007377
Other languages
English (en)
French (fr)
Other versions
WO2005004906A2 (de
Inventor
Siegfried Ansorge
Harald Gollnick
Uwe Lendeckel
Klaus Neubert
Dirk Reinhold
Robert Vetter
Burkhart Schraven
Anja Thielitz
Juergen Faust
Original Assignee
Inst Medizintechnologie Magdeb
Siegfried Ansorge
Harald Gollnick
Uwe Lendeckel
Klaus Neubert
Dirk Reinhold
Robert Vetter
Burkhart Schraven
Anja Thielitz
Juergen Faust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Medizintechnologie Magdeb, Siegfried Ansorge, Harald Gollnick, Uwe Lendeckel, Klaus Neubert, Dirk Reinhold, Robert Vetter, Burkhart Schraven, Anja Thielitz, Juergen Faust filed Critical Inst Medizintechnologie Magdeb
Priority to US10/563,498 priority Critical patent/US20070042938A1/en
Priority to JP2006518125A priority patent/JP2009513520A/ja
Priority to EP04740701A priority patent/EP1644033A2/de
Publication of WO2005004906A2 publication Critical patent/WO2005004906A2/de
Publication of WO2005004906A3 publication Critical patent/WO2005004906A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Hemmung der für die Proliferation notwendigen DNA-Synthese von humanen Fibroblasten durch die alleinige oder gemeinsame Wirkung von Inhibitoren der von diesen Zellen exprimierten Alanyl-Aminopeptidase (APN) und Dipeptidylpeptidase IV (DP IV). Die DNA-Synthese (Proliferation) humaner Fibroblasten wird durch Gabe von Inhibitoren der APN oder/und der DP IV dosisabhängig gehemmt. Unsere Erfindung zeigt, dass zur Therapie und Prävention von dermatologischen Erkrankungen mit fibroblastärer Hyperproliferation und veränderten fibroblastären Differenzierungszuständen die Applikation von Hemmstoffen der oben genannten Enzyme bzw. von diese Hemmstoffe enthaltenden Zubereitungen und Darreichungsformen daraus geeignet sind.
PCT/EP2004/007377 2003-07-08 2004-07-06 Verwendung von dp iv- und apn inhibitoren zur behandlung dermatologischer erkrankungen mit hyperproliferation und veränderten differenzierungszuständen von fibroblasten WO2005004906A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/563,498 US20070042938A1 (en) 2003-07-08 2004-07-06 Use of dpiv and apn inhibitors for the treatment of dermatalogical diseases involving the hyperproliferation and modified differentiation conditions of fibroblasts
JP2006518125A JP2009513520A (ja) 2003-07-08 2004-07-06 線維芽細胞の過剰増殖および分化状態の変化を含む皮膚疾患の治療ならびに予防のための、アミノペプチダーゼｎおよび／またはジペプチジルペプチダーゼｉｖの活性を有する酵素の阻害剤の使用、ならびにそれらを含有する医薬調製品の使用
EP04740701A EP1644033A2 (de) 2003-07-08 2004-07-06 Verwendung von dp iv- und apn inhibitoren zur behandlung dermatologischer erkrankungen mit hyperproliferation und veraenderten differenzierungszustaenden von fibroblasten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10330842A DE10330842A1 (de) 2003-07-08 2003-07-08 Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit Hyperproliferation und veränderten Differenzierungszuständen von Fibroblasten
DE10330842.3 2003-07-08

Publications (2)

Publication Number Publication Date
WO2005004906A2 WO2005004906A2 (de) 2005-01-20
WO2005004906A3 true WO2005004906A3 (de) 2005-06-09

Family

ID=34041691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007377 WO2005004906A2 (de) 2003-07-08 2004-07-06 Verwendung von dp iv- und apn inhibitoren zur behandlung dermatologischer erkrankungen mit hyperproliferation und veränderten differenzierungszuständen von fibroblasten

Country Status (6)

Country Link
US (1) US20070042938A1 (de)
EP (1) EP1644033A2 (de)
JP (1) JP2009513520A (de)
CN (1) CN100560129C (de)
DE (1) DE10330842A1 (de)
WO (1) WO2005004906A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
DE102005054700B4 (de) 2005-11-16 2009-01-08 Imtm Gmbh Neue duale Peptidase-Inhibitoren als Prodrugs zur Therapie von entzündlichen und anderen Erkrankungen
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2292589A1 (de) 2009-09-02 2011-03-09 IMTM GmbH Neue multifunktionale Peptidaseinhibitoren, insbesondere zur medizinischen Verwendung
EP2366394A1 (de) 2010-03-17 2011-09-21 IMTM GmbH Charakterisierung und Validierung von Inhibitoren und Liganden der Dipeptidyl-Aminopeptidase IV (DP IV)
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
KR101938981B1 (ko) 2017-07-07 2019-01-15 중앙대학교 산학협력단 류히스틴을 유효성분으로 포함하는 피임용 약학적 조성물
WO2019112031A1 (ja) * 2017-12-08 2019-06-13 サイエンスファーム株式会社 全身性強皮症治療剤
CN112341356B (zh) * 2019-08-09 2023-04-28 成都苑东生物制药股份有限公司 (2s,3r)-3-氨基-2-羟基-4-苯丁酰氨衍生物、其制备方法及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939560A (en) * 1993-12-03 1999-08-17 Ferring B.V. Inhibitors of DP-mediated processes, compositions and therapeutic methods thereof
DE10025464A1 (de) * 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
WO2002053170A2 (de) * 2001-01-02 2002-07-11 Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) Kombinierte verwendung von enzyminhibitoren und pharmazeutischen zubereitungen daraus zur therapie und prophylaxe der arteriosklerose, zur therapie und prävention allergischer reaktionen von typ i nach gell und coombs und zur therapie und prävention dermatologischer erkrankungen mit follikulären und epidermalen hyperkeratos
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000484A1 (en) * 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US6090786A (en) * 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
WO2001039795A2 (en) * 1999-12-02 2001-06-07 Ibex Technologies, Inc. Attenuation of fibroblast proliferation
DE10002820A1 (de) * 2000-01-24 2001-08-23 Walter Schubert Aminopeptidasen-Inhibitor
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
DE10155093A1 (de) * 2001-11-09 2003-06-12 Inst Medizintechnologie Magdeb Kombinierte Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit follikulären und epidermalen Hyperkeratosen und einer verstärkten Keratinozytenproliferation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939560A (en) * 1993-12-03 1999-08-17 Ferring B.V. Inhibitors of DP-mediated processes, compositions and therapeutic methods thereof
DE10025464A1 (de) * 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
WO2002053170A2 (de) * 2001-01-02 2002-07-11 Institut Für Medizintechnologie Magdeburg Gmbh (Imtm) Kombinierte verwendung von enzyminhibitoren und pharmazeutischen zubereitungen daraus zur therapie und prophylaxe der arteriosklerose, zur therapie und prävention allergischer reaktionen von typ i nach gell und coombs und zur therapie und prävention dermatologischer erkrankungen mit follikulären und epidermalen hyperkeratos
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL JOURNAL, vol. 216, no. 1, 1983, pages 177 - 184, ISSN: 0264-6021 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1983, SAISON M ET AL: "IDENTIFICATION OF CELL SURFACE DI PEPTIDYL PEPTIDASE IV EC-3.4.14.5 IN HUMAN FIBROBLASTS", XP002308342, Database accession no. PREV198477050630 *
DIMON-GADAL STEPHANIE ET AL: "MAP kinase abnormalities in hyperproliferative cultured fibroblasts from psoriatic skin", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 110, no. 6, June 1998 (1998-06-01), pages 872 - 879, XP002308341, ISSN: 0022-202X *
FUJII HIDEJI ET AL: "Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitors", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 19, no. 1, 1996, pages 6 - 10, XP001204025, ISSN: 0918-6158 *
RAYNAUD F ET AL: "CHARACTERIZATION OF SPECIFIC PROTEASES ASSOCIATED WITH THE SURFACE OF HUMAN SKIN FIBROBLASTS AND THEIR MODULATION IN PATHOLOGY", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 151, no. 2, 1992, pages 378 - 385, XP009040761, ISSN: 0021-9541 *

Also Published As

Publication number Publication date
JP2009513520A (ja) 2009-04-02
CN1819840A (zh) 2006-08-16
WO2005004906A2 (de) 2005-01-20
CN100560129C (zh) 2009-11-18
EP1644033A2 (de) 2006-04-12
DE10330842A1 (de) 2005-02-10
US20070042938A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2005004906A3 (de) Verwendung von dp iv- und apn inhibitoren zur behandlung dermatologischer erkrankungen mit hyperproliferation und veränderten differenzierungszuständen von fibroblasten
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
WO2002056900A3 (de) Verwendung von slpi zur behandlung chronisch-entzündlicher darmerkrankungen
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2007089851A3 (en) Compositions and methods for treating collagen-mediated diseases
TW200505416A (en) Bi-aryl compound having immunosuppressive activity
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2002074992A3 (en) Phosphodiesterase 4d genes related to human stroke
WO2005105094A3 (en) Cancer treatment method
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
MXPA06004308A (es) Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables.
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
DK1487475T3 (da) Farmaceutiske tilberedninger af inhibitorer for aminopeptidase N alene eller sammen med inhibitorer for dipeptidylpeptidase IV til terapi og forebyggelse af dermatologiske sygdomme med seboroisk hyperproliferation og ændrede differentieringstilstande
WO2005082884A3 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease
AU4910500A (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2004030684A3 (en) Kavalactone product

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480019624.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004740701

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006518125

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004740701

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007042938

Country of ref document: US

Ref document number: 10563498

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10563498

Country of ref document: US